Meeting
2022 ASCO Annual Meeting
Dysfunctional CD8+ T cells in the tumor microenvironment are associated with response to nivolumab in mismatch repair deficient (dMMR) or hypermutated ovarian (OVCA) or endometrial cancer (EC).
Authors
Claire Frances Friedman
Memorial Sloan Kettering Cancer Center and Weill Medical College at Cornell University, New York, NY
Claire Frances Friedman , Qin Zhou , Alexia Iasonos , Aliya Holland , Lizbeth Ramirez , Rachel N. Grisham , Robin Guo , Stuart M. Lichtman , Chrisann Kyi , Vicky Makker , Jennifer Jean Mueller , Roisin Eilish O'Cearbhaill , Alison M. Schram , William P. Tew , Jason A. Konner , Tiffany A. Troso-Sandoval , Andreas Georg Wibmer , Carol Aghajanian , Martee Leigh Hensley , Dmitriy Zamarin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Uterine Cancer
Clinical Trial Registration Number
NCT03241745
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 5583)
DOI
10.1200/JCO.2022.40.16_suppl.5583
Abstract #
5583
Poster Bd #
459
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Biomarker analysis to predict response in patients with metastatic mismatch repair proficient colorectal cancer treated with regorafenib and nivolumab.
First Author: Ruoyu Miao
Poster
2022 ASCO Annual Meeting
Impact of RAS mutations on immunologic characteristics of the tumor microenvironment (TME) in patients with microsatellite instability-high (MSI-H) or mismatch-repair–deficient (dMMR) colorectal cancer (CRC).
First Author: Mohamed E. Salem
Poster
2019 ASCO Annual Meeting
Anti-PD-1/PD-L1 plus chemotherapy versus chemotherapy alone in first-line treatment for patients with metastatic NSCLC that were PD-L1 negative or less than 1 %.
First Author: Thierry Landre
Poster
2019 ASCO Annual Meeting
AtTEnd/ENGOT-en7: A multicenter phase III double-blind randomized controlled trial of atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer.
First Author: Nicoletta Colombo